Kala Pharmaceuticals (KALA) Set to Announce Quarterly Earnings on Tuesday

Kala Pharmaceuticals (NASDAQ:KALA) will issue its quarterly earnings data before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.75). The firm had revenue of $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. On average, analysts expect Kala Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of Kala Pharmaceuticals stock opened at $5.80 on Monday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 9.93 and a current ratio of 10.30. The company has a market capitalization of $196.50 million, a price-to-earnings ratio of -2.34 and a beta of 2.02. Kala Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $14.45. The company has a 50-day moving average price of $5.88.

KALA has been the subject of several research analyst reports. ValuEngine raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Oppenheimer initiated coverage on Kala Pharmaceuticals in a report on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. BidaskClub lowered Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Zacks Investment Research raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a report on Saturday. Finally, Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 5th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $19.39.

In related news, Director Howard B. Rosen bought 5,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $27,100.00. Following the completion of the purchase, the director now directly owns 8,240 shares in the company, valued at approximately $44,660.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 30.77% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: What is the downside to momentum investing?

Earnings History for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.